These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18377780)

  • 1. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 2. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 3. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Diab Rep; 2008 Jun; 8(3):165-7. PubMed ID: 18625111
    [No Abstract]   [Full Text] [Related]  

  • 4. Will CETP inhibition survive the demise of torcetrapib?
    Olsson AG
    Curr Atheroscler Rep; 2008 Apr; 10(2):97-9. PubMed ID: 18417061
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
    Duriez P
    Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843
    [No Abstract]   [Full Text] [Related]  

  • 6. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL cholesterol and atherosclerosis.
    Mazzone T
    Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CETP Inhibition: does the future look promising?
    Toth PP
    Curr Cardiol Rep; 2011 Dec; 13(6):559-65. PubMed ID: 21909703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 15. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 16. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 17. New horizons for cholesterol ester transfer protein inhibitors.
    Schwartz GG
    Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 20. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.